Fig. 1: Kaplan–Meier plots showing cumulative hazard among people reporting a positive test on the LFIA (grey line) and those reporting a negative test (red line) for (from top left to bottom right) (i) all-cause hospitalisation, (ii) emergency hospitalisation, (iii) hospitalisation with COVID-19 as the primary diagnosis, (iv) hospitalisation with COVID-19 mentioned anywhere on the hospital record, and (v) all-cause mortality, among N = 192,604 participants who had received one or more vaccines. | Nature Communications

Fig. 1: Kaplan–Meier plots showing cumulative hazard among people reporting a positive test on the LFIA (grey line) and those reporting a negative test (red line) for (from top left to bottom right) (i) all-cause hospitalisation, (ii) emergency hospitalisation, (iii) hospitalisation with COVID-19 as the primary diagnosis, (iv) hospitalisation with COVID-19 mentioned anywhere on the hospital record, and (v) all-cause mortality, among N = 192,604 participants who had received one or more vaccines.

From: SARS-CoV-2 rapid antibody test results and subsequent risk of hospitalisation and death in 361,801 people

Fig. 1: Kaplan–Meier plots showing cumulative hazard among people reporting a positive test on the LFIA (grey line) and those reporting a negative test (red line) for (from top left to bottom right) (i) all-cause hospitalisation, (ii) emergency hospitalisation, (iii) hospitalisation with COVID-19 as the primary diagnosis, (iv) hospitalisation with COVID-19 mentioned anywhere on the hospital record, and (v) all-cause mortality, among N = 192,604 participants who had received one or more vaccines.

95% pointwise confidence intervals are shown in shaded colour.

Back to article page